Gastrointestinal Perforation Rare in Rheumatoid Arthritis

Share this article:
Gastrointestinal Perforation Rare in Rheumatoid Arthritis
Gastrointestinal Perforation Rare in Rheumatoid Arthritis

(HealthDay News) – Gastrointestinal (GI) perforation is a rare but serious condition that affects patients with rheumatoid arthritis (RA), most frequently in the lower GI tract.

Jeffrey R. Curtis, MD, MPH, from the University of Alabama at Birmingham, and colleagues analyzed health insurance claims data to identify the incidence and risk factors for GI perforation among 143,433 RA patients.

Using a maximally sensitive definition for GI perforation, the researchers identified 696 hospitalizations with perforation, representing a rate of 1.7 per 1,000 person-years, which was lower when a more specific definition was used (0.87 per 1,000 person years). Eighty-three percent of perforations occurred in the lower GI tract. Age and diverticulitis were the strongest risk factors for perforation (hazard ratios for diverticulitis: 14.5 for the more sensitive definition and 3.9 for the more specific definition). The risk of GI perforation was highest among patients with exposure to concomitant non-biologic disease-modifying antirheumatic drugs and glucocorticoids, compared to methotrexate. Use of biologics without glucocorticoids was not a risk factor.

"Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or nonsteroidal anti-inflammatory drugs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies; one author is an employee of Genentech.

Abstract
Full Text (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs